Plain-English translation of NCT07909265 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two medications called cadonilimab and lenvatinib to treat advanced kidney cancer. The trial is designed for patients whose kidney cancer has already progressed after other treatments. Researchers want to see if this combination can slow or stop cancer growth while being tolerable for patients to take.
Many people with advanced kidney cancer stop responding to their first treatment options. This medication combination is being tested to see if it offers a new hope for patients whose cancer has returned or worsened, particularly those who didn't benefit from previous immunotherapy.
You likely qualify if…
You likely don't qualify if…
You'll have a screening visit within 28 days to confirm you qualify for the study. If enrolled, you'll receive the two medications in 3-week cycles, with scans to check your cancer every 6 weeks. You'll continue treatment as long as the cancer isn't progressing and you can tolerate the side effects. After treatment ends, you'll have a safety check-up 30 days later, then phone or in-person check-ins every 3 months for one year to track how you're doing.
AI-generated summary from trial data · Nov 3, 2026 · Not medical advice
China